Comparison of Constipation caused by High-dose Metoclopramide and 5-HT3 Antagonist Antiemetic Drugs in Patients. Receiving MVP Chemotherapy for Lung Cancer.

概要

論文の詳細を見る
We retrospectively investigated the frequency of constipation in 63 patients receiving MVP chemotherapy (MMC, VDS, CDDP) for non-small cell lung cancer. We divided them into two groups according to the antiemetic drugs they received, one was the high-dose metoclopramide group, and the other was the 5-HT3 antagonist group, and compared the two groups. Constipation occurred in 13%(3/23) of patients given high-dose metoclopramide, and in 45%(18/40) of those given 5-HT3 antagonist. This result may be due to combination of the three following factors; diarrhea induced by high dose metoclopramide, constipation induced by 5-HT3 antagonists and constipation induced by MVP chemotherapy. 5-HT3 antagonists are effective and indispensable for lung cancer chemotherapy. Although no other studies have reported constipation due to MVP chemotherapy with 5-HT3 antagonist in Japan, we should be aware of the possibility of constipation induced by 5-HT3 antagonist.
特定非営利活動法人日本肺癌学会の論文